back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2023-05-10 17:46 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
780,000 | |
| Filed 2023-01-27 10:09 Tx date 2023-01-26 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
680,000 | |
| Filed 2023-01-18 10:03 Tx date 2023-01-17 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$26,499
+294,444 vol $0.09 each |
1,193,426 | |
| Filed 2023-01-03 14:20 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+50,200 vol |
50,200 | |
| Filed 2023-01-03 14:20 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-01-03 14:20 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$10,040
+100,400 vol $0.10 each |
898,982 | |
| Filed 2021-06-17 11:43 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$120,000
+300,000 vol $0.40 each |
380,000 | |
| Filed 2021-06-03 17:28 Tx date 2021-06-02 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
$8,249
+21,428 vol $0.385 each |
798,582 | |
| Filed 2020-08-20 17:56 Tx date 2020-08-18 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$21,498
+119,438 vol $0.18 each |
777,154 | |
| Filed 2019-10-29 18:27 Tx date 2019-10-29 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$9,749
+34,821 vol $0.28 each |
657,716 | |
| Filed 2019-01-17 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-01-17 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
80,000 | ||
| Filed 2019-01-17 Tx date 2019-01-15 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$170,000
+357,895 vol $0.475 each |
622,895 | |
| Filed 2018-12-14 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
265,000 | ||
| Filed 2018-12-14 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|